QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QN-302’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QN-302 overview
QN-302 is under development for the treatment of solid tumors such as pancreatic ductal adenocarcinoma (PDAC), sarcomas, prostate cancer, metastatic colorectal cancer and gastrointestinal stromal tumor (GIST). It acts by targeting genomic quadruplex (G4). It is administered through intravenous route.
Qualigen Therapeutics overview
Qualigen Therapeutics (Qualigen) is a clinical-stage therapeutics company that focuses on developing treatments for adult and pediatric cancer. Its therapeutics pipeline products include QN-302 which is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; Pan-RAS which is a oncogene protein-protein interaction inhibitor small molecules inhibit or block the binding of mutated RAS genes proteins to their effector proteins which leaves the proteins from the mutated RAS unable to cause further harm and treats pancreatic, colorectal, and lung cancers. Qualigen is headquartered in Los Angeles, California, the US.
For a complete picture of QN-302’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
